查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566934

癌症診斷市場中的人工智慧：按組件、類型和最終用戶分類：2024-2033 年全球機會分析和產業預測

Artificial Intelligence In Cancer Diagnostics Market By Component , By Type By End user : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，癌症診斷領域的人工智慧市場價值為2億美元，預計2024年至2033年複合年成長率為23.6%，到2033年將達到17億美元。

人工智慧正在幫助醫療保健專業人員檢測、分析和治療各種類型的癌症，從而改變癌症診斷。透過利用先進的演算法和機器學習技術，人工智慧可以提高診斷過程的準確性、速度和效率，為患者和醫療保健專業人員帶來顯著的好處。人工智慧有潛力透過賦予醫療保健工作者權力和簡化診斷過程來改善患者的治療結果並推動對抗癌症的鬥爭。

全球癌症診斷人工智慧市場的成長是由全球各類癌症盛行率的驚人成長以及對先進診斷工具來管理和治療不斷增加的病例的需求所推動的。根據世界衛生組織 (WHO) 估計，2022 年將有 2,000 萬名癌症患者和 970 萬人死亡。此外，對癌症早期檢測和製定個人化治療計劃的需求不斷成長，推動了對人工智慧改善患者治療效果的需求。此外，與癌症診斷中的人工智慧相關的多種好處也對市場成長做出了重大貢獻。例如，人工智慧不僅可以透過支援放射科醫生和病理學家來幫助減輕醫療系統的負擔，而且人工智慧主導的診斷可以透過簡化流程和減少錯誤來改善醫療保健。此外，公眾和專業人士對醫療保健領域人工智慧的認知和接受程度不斷提高，也大大推動了市場的成長。然而，實施人工智慧所需的高額初始投資，如技術取得、培訓和維護，是全球市場的主要阻礙因素。將人工智慧系統與現有的醫療基礎設施和電子健康記錄整合非常複雜，並且會產生額外的成本，從而限制了市場的成長。此外，人工智慧和醫療保健領域專家的缺乏限制了人工智慧解決方案的採用和開發。相反，將人工智慧納入遠端醫療平台以提供遠距離診斷服務預計將為預測期內全球市場的擴張提供利潤豐厚的機會。據美國國家癌症美國稱，在大流行期間進行了約 25,500 次遠端醫療，其中莫菲特癌症中心的臨床醫生進行了超過 11,600次遠距醫療訪問，莫菲特癌症中心是美國癌症研究所指定的位於佛羅裡達州的虛擬癌症中心。這樣，遠端醫療服務中的人工智慧就可以對慢性病患者進行持續監測。此外，使用人工智慧分析血液樣本提供了非侵入性診斷選擇，預計將為市場成長開闢新的途徑。

癌症診斷人工智慧的全球市場按組件、類型、最終用戶和地區進行細分。按組成部分，市場分為軟體、服務和硬體。依類型分為乳癌、肺癌、攝護腺癌等。依最終用戶分類，該細分市場可分為醫院、診斷中心等。按地區分類，對北美、歐洲、亞太地區和拉丁美洲地區市場進行了分析。

主要發現

從組成部分來看，到 2023 年，軟體領域將在癌症診斷市場的人工智慧領域佔據主導地位。

按類型分類，預計到 2033 年乳癌細分市場將引領市場。

按最終用戶分類，醫院領域在 2023 年呈現最高成長。

按地區分類，北美很可能在 2023 年成為主要收益來源，並在預測期內主導市場。

可以自訂此報告（需要額外的費用和時間表）

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 主要投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章癌症診斷中的人工智慧市場：按組成部分

  • 市場概況
  • 軟體
  • 服務
  • 硬體

第5章癌症診斷中的人工智慧市場：按類型

  • 市場概況
  • 乳癌
  • 肺癌
  • 攝護腺癌
  • 其他

第6章癌症診斷中的人工智慧市場：按最終用戶分類

  • 市場概況
  • 醫院
  • 診斷中心
  • 其他

第7章癌症診斷中的人工智慧市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國癌症診斷的人工智慧市場
    • 加拿大癌症診斷的人工智慧市場
    • 墨西哥癌症診斷中的人工智慧市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 法國癌症診斷中的人工智慧市場
    • 德國癌症診斷中的人工智慧市場
    • 義大利癌症診斷的人工智慧市場
    • 西班牙癌症診斷中的人工智慧市場
    • 英國癌症診斷中的人工智慧市場
    • 癌症診斷人工智慧的其他歐洲國家市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 中國癌症診斷的人工智慧市場
    • 日本癌症診斷中的人工智慧市場
    • 印度癌症診斷中的人工智慧市場
    • 韓國癌症診斷中的人工智慧市場
    • 澳洲癌症診斷中的人工智慧市場
    • 其他亞太地區癌症診斷人工智慧市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西癌症診斷中的人工智慧市場
    • 南非癌症診斷中的人工智慧市場
    • 沙烏地阿拉伯癌症診斷中的人工智慧市場
    • 拉丁美洲、中東和非洲癌症診斷人工智慧的其他市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • Siemens Healthineers AG
  • Nanox Imaging LTD
  • Riverain Technologies
  • Vuno, Inc.
  • Aidoc
  • Neural Analytics
  • Imagen Technologies
  • Digital Diagnostics
  • GE Healthcare
  • AliveCor Inc.
簡介目錄
Product Code: A323966

The artificial intelligence in cancer diagnostics market was valued at $0.2 billion in 2023, and is projected to reach $1.7 billion by 2033, growing at a CAGR of 23.6% from 2024 to 2033.

Artificial intelligence is transforming cancer diagnostics by helping healthcare professionals to detect, analyze, and treat various types of cancer. By leveraging advanced algorithms and machine learning techniques, artificial intelligence enhances the accuracy, speed, and efficiency of diagnostic processes, offering significant benefits to both patients and medical practitioners. Artificial intelligence holds the potential to improve patient outcomes and advance the fight against cancer by enhancing the capabilities of medical professionals and streamlining diagnostic processes.

The growth of the global artificial intelligence in cancer diagnostics market is majorly driven by alarming increase in prevalence of various types of cancer worldwide, which necessitates advanced diagnostic tools to manage and treat the growing number of cases. According to the estimates of the World Health Organization, 20 million cancer cases and 9.7 million deaths were reported in 2022. Moreover, rise in need for early cancer detection and development of personalized treatment plans fosters the need for artificial intelligence to improve patient outcomes. In addition, multiple benefits associated with artificial intelligence in cancer diagnostics significantly contributes toward the market growth. For instance, artificial intelligence helps to alleviate the burden on healthcare systems by supporting radiologists and pathologists as well as artificial intelligence-driven diagnostics can reduce healthcare costs by streamlining processes and minimizing errors. Furthermore, growing awareness and acceptance of artificial intelligence in healthcare among the public and professionals is considerably propelling the market growth. However, high initial investment required for implementation of artificial intelligence, including technology acquisition, training, and maintenance acts as a key deterrent factor of the global market. Integrating artificial intelligence systems with existing healthcare infrastructure and electronic health records is complex and incurs additional cost, thereby restraining the growth of the market. Moreover, dearth of professionals with expertise in both artificial intelligence and healthcare limits the adoption and development of artificial intelligence solutions. On the contrary, incorporating artificial intelligence with telemedicine platforms to provide remote diagnostic services is expected to offer remunerative opportunities for the expansion of the global market during the forecast period. According to the National Cancer Institute, approximately 25,500 telehealth visits were conducted during the pandemic, among which over 11,600 were adult cancer patients who received virtual consultations from clinicians at the Moffitt Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center located in Florida. Thus, artificial intelligence in telehealth services will enable continuous monitoring of patients with chronic conditions. Furthermore, using artificial intelligence to analyze blood samples offers a non-invasive diagnostic option, which is anticipated to open new avenues for the growth of the market.

The global artificial intelligence in cancer diagnostics market is segmented into component, type, end user, and region. By component, the market is categorized into software, services, and hardware. On the basis of type, it is classified into breast cancer, lung cancer, prostate cancer, and others. Depending on end user, it is fragmented into hospitals, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By component, the software segment dominated the artificial intelligence in cancer diagnostics market in 2023.

On the basis of type, the breast cancer segment is expected to lead the market by 2033.

Depending on end user, the hospital segment exhibited the highest growth in 2023.

Region wise, North America was the major revenue generator in 2023, and is likely to dominate the market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global artificial intelligence in cancer diagnostics market include Siemens Healthineers AG, Nanox Imaging LTD, Riverain Technologies, Vuno, Inc., Aidoc, Neural Analytics, Imagen Technologies, Digital Diagnostics, GE Healthcare, and AliveCor Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Component

  • Software
  • Services
  • Hardware

By Type

  • Breast cancer
  • Lung cancer
  • Prostate cancer
  • Others

By End User

  • Hospitals
  • Diagnostic centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Siemens Healthineers AG
    • Nanox Imaging LTD
    • Riverain Technologies
    • Vuno, Inc.
    • Aidoc
    • Neural Analytics
    • Imagen Technologies
    • Digital Diagnostics
    • GE Healthcare
    • AliveCor Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Component
  • 4.2. Software
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Services
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Hardware
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Type
  • 5.2. Breast Cancer
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Lung Cancer
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Prostate Cancer
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Others
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Diagnostic Centers
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Others
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Component
    • 7.2.3. Market Size and Forecast, By Type
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Artificial Intelligence In Cancer Diagnostics Market
      • 7.2.6.1. Market Size and Forecast, By Component
      • 7.2.6.2. Market Size and Forecast, By Type
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Artificial Intelligence In Cancer Diagnostics Market
      • 7.2.7.1. Market Size and Forecast, By Component
      • 7.2.7.2. Market Size and Forecast, By Type
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Artificial Intelligence In Cancer Diagnostics Market
      • 7.2.8.1. Market Size and Forecast, By Component
      • 7.2.8.2. Market Size and Forecast, By Type
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Component
    • 7.3.3. Market Size and Forecast, By Type
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.6.1. Market Size and Forecast, By Component
      • 7.3.6.2. Market Size and Forecast, By Type
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. Germany Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.7.1. Market Size and Forecast, By Component
      • 7.3.7.2. Market Size and Forecast, By Type
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. Italy Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.8.1. Market Size and Forecast, By Component
      • 7.3.8.2. Market Size and Forecast, By Type
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Spain Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.9.1. Market Size and Forecast, By Component
      • 7.3.9.2. Market Size and Forecast, By Type
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. UK Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.10.1. Market Size and Forecast, By Component
      • 7.3.10.2. Market Size and Forecast, By Type
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Artificial Intelligence In Cancer Diagnostics Market
      • 7.3.11.1. Market Size and Forecast, By Component
      • 7.3.11.2. Market Size and Forecast, By Type
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Component
    • 7.4.3. Market Size and Forecast, By Type
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.6.1. Market Size and Forecast, By Component
      • 7.4.6.2. Market Size and Forecast, By Type
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. Japan Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.7.1. Market Size and Forecast, By Component
      • 7.4.7.2. Market Size and Forecast, By Type
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.8.1. Market Size and Forecast, By Component
      • 7.4.8.2. Market Size and Forecast, By Type
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. South Korea Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.9.1. Market Size and Forecast, By Component
      • 7.4.9.2. Market Size and Forecast, By Type
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. Australia Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.10.1. Market Size and Forecast, By Component
      • 7.4.10.2. Market Size and Forecast, By Type
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Artificial Intelligence In Cancer Diagnostics Market
      • 7.4.11.1. Market Size and Forecast, By Component
      • 7.4.11.2. Market Size and Forecast, By Type
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Component
    • 7.5.3. Market Size and Forecast, By Type
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Artificial Intelligence In Cancer Diagnostics Market
      • 7.5.6.1. Market Size and Forecast, By Component
      • 7.5.6.2. Market Size and Forecast, By Type
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. South Africa Artificial Intelligence In Cancer Diagnostics Market
      • 7.5.7.1. Market Size and Forecast, By Component
      • 7.5.7.2. Market Size and Forecast, By Type
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. Saudi Arabia Artificial Intelligence In Cancer Diagnostics Market
      • 7.5.8.1. Market Size and Forecast, By Component
      • 7.5.8.2. Market Size and Forecast, By Type
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Artificial Intelligence In Cancer Diagnostics Market
      • 7.5.9.1. Market Size and Forecast, By Component
      • 7.5.9.2. Market Size and Forecast, By Type
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Siemens Healthineers AG
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Nanox Imaging LTD
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Riverain Technologies
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Vuno, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Aidoc
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Neural Analytics
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Imagen Technologies
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Digital Diagnostics
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. GE Healthcare
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. AliveCor Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments